Investor Event Our Path to Sustained Revenue and Earnings Growth Through 2030 March 19, 2026 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; long-term financial targets; base case long-term target CAGR of 3-4% for Total Revenues, 4-5% for Adjuste ...

Core Viewpoint - Lake Street analyst upgraded PubMatic (PUBM) to Buy from Hold with a price target increase to $10 from $9.50, citing a strong Q4 performance that exceeded revenue and adjusted EBITDA expectations, marking an "inflection quarter" [1] Group 1: Performance and Expectations - PubMatic's Q4 results surpassed expectations in both revenue and adjusted EBITDA, indicating a positive shift in performance [1] - The firm anticipates that revenue and earnings will return to growth in Q3, suggesting a recovery trajectory for the company [1] Group 2: Market Conditions and Valuation - The stabilization of DSP disruption is seen as a positive factor for the company's outlook [1] - Q4 is expected to benefit from a political advertising kicker, which could further enhance revenue [1] - Shares of PubMatic are considered "dirt cheap," indicating a favorable valuation perspective [1]

Core Insights - Ascendis Pharma A/S is a biopharmaceutical company focused on developing treatments for unmet medical needs, with products like SKYTROFA for growth hormone deficiency (GHD) and ongoing development of other treatments [1] Price Target Trends - The consensus price target for Ascendis Pharma has increased from $221.33 to $254 over the past year, indicating growing optimism among analysts regarding the company's future prospects [2][6] - Despite a lower price target of $161 set by Bank of America Securities analyst Tazeen Ahmad, the overall sentiment remains positive [2] Product Developments - Significant product developments, such as the approval of SKYTROFA for adults with GHD and the Priority Review of TransCon CNP by the U.S. FDA, have likely contributed to the positive analyst sentiment [3][6] - Progress with TransCon Growth Hormone and other treatments is crucial in shaping analyst outlook [3] Market Expansion - Ascendis Pharma's expansion into new markets, including Japan for pediatric GHD, has positively influenced analyst sentiment [4] - The global uptake of YORVIPATH further emphasizes the company's market expansion strategy [4] Financial Performance - In Q2 2025, Ascendis Pharma reported significant revenues of €103 million from YORVIPATH and €50.7 million from SKYTROFA, which likely bolsters analyst confidence in the company's growth potential [5][6] - Successful funding rounds also contribute to the positive trend in price targets [5]

Group 1 - Cooper-Standard (CPS) reported disappointing Q3 earnings, with revenue and earnings falling below guidance [1] - Management has reduced the revenue and adjusted EBITDA guidance for 2025 due to production disruptions at Ford [1] Group 2 - The article reflects a long-term investment strategy focused on identifying companies with high potential for revenue and earnings growth [1] - The author emphasizes a preference for investing in less cyclical and higher growth sectors, with a geographical bias towards the United States [1]